Lexicon Pharmaceuticals (LXRX) Change in Acquisitions & Divestments (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Change in Acquisitions & Divestments for 17 consecutive years, with $35.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 66.18% year-over-year to $35.7 million; the TTM figure through Mar 2026 stood at $183.0 million (down 47.25% YoY), while the FY2025 annual figure was $252.9 million, down 19.57% from the prior year.
• Change in Acquisitions & Divestments rose to $35.7 million in Q1 2026 per LXRX's latest filing, from $27.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $105.6 million in Q1 2025 and bottomed at $8.7 million in Q2 2022.
• Historically, Change in Acquisitions & Divestments has averaged $49.5 million across 5 years, with a median of $41.5 million in 2025.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments surged 447.43% — and 2025, when it plunged 66.25%.
• Lexicon Pharmaceuticals' Change in Acquisitions & Divestments stood at $26.0 million in 2022, then jumped by 99.95% to $52.0 million in 2023, then soared by 53.85% to $80.0 million in 2024, then slumped by 66.25% to $27.0 million in 2025, then surged by 32.21% to $35.7 million in 2026.
• Business Quant data shows LXRX's Change in Acquisitions & Divestments at $35.7 million in Q1 2026, $27.0 million in Q4 2025, and $78.8 million in Q3 2025.